Organogenesis Holdings Inc. stock is down -4.51% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 February’s closed higher than January. 100% of analysts rate it a buy.
Organogenesis Holdings Inc. develops, manufactures, and commercializes solutions for the advanced wound care, surgical and sports medicine markets in the United States. The company's products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved. NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; NuShield is a wound-covering tissue. NuCel is a dehydrated placental tissue surgically applied to the target tissue to support native healing. Nu
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!